期刊
GENE THERAPY
卷 10, 期 3, 页码 272-277出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3301877
关键词
recombinant Sendai virus; cord blood; hematopoietic stem cells; CD34(+) cells; gene therapy
Hematopoietic stem cells (HSCs) are a promising target for gene therapy, however, the low efficiencies of gene transfer using currently available vectors face practical limitations. We have recently developed a novel and efficient gene transfer agent, namely recombinant Sendai virus (SeV), and we have here characterized SeV-mediated gene transfer to human cord blood (CB) HSCs and primitive progenitor cells (PPC) using the jelly fish green fluorescent protein (GFP) gene. Even at a relatively low titer (10 multiplicity of infections), SeV achieved highly efficient GFP expression in CB CD34(+) cells (85.5 +/- 5.8%), as well as more immature CB progenitor cells, CD34(+)AC133(+) (88.2 +/- 3.7%) and CD34(+)CD38(-) (84.6 +/- 5.7%) cells, without cytokines prestimulation, that was a clear contrast to the features of gene transfer using retroviruses. SeV-mediated gene transfer was not seriously affected by the cell cycle status. In vitro cell differentiation studies revealed that gene transfer occurred in progenitor cells of all lineages (GM-CFU, 73.0 +/- 11.1 %; BFU-E, 24.7 +/- 4.0%; Mix-CFU, 59 +/- 4.0%; and total, 50.0 +/- 7.0%). These findings show that Se V could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据